Literature DB >> 19150053

Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.

Andrew H Miller1, Vladimir Maletic, Charles L Raison.   

Abstract

Recognition that inflammation may represent a common mechanism of disease has been extended to include neuropsychiatric disorders including major depression. Patients with major depression have been found to exhibit increased peripheral blood inflammatory biomarkers, including inflammatory cytokines, which have been shown to access the brain and interact with virtually every pathophysiologic domain known to be involved in depression, including neurotransmitter metabolism, neuroendocrine function, and neural plasticity. Indeed, activation of inflammatory pathways within the brain is believed to contribute to a confluence of decreased neurotrophic support and altered glutamate release/reuptake, as well as oxidative stress, leading to excitotoxicity and loss of glial elements, consistent with neuropathologic findings that characterize depressive disorders. Further instantiating the link between inflammation and depression are data demonstrating that psychosocial stress, a well-known precipitant of mood disorders, is capable of stimulating inflammatory signaling molecules, including nuclear factor kappa B, in part, through activation of sympathetic nervous system outflow pathways. Interestingly, depressed patients with increased inflammatory biomarkers have been found to be more likely to exhibit treatment resistance, and in several studies, antidepressant therapy has been associated with decreased inflammatory responses. Finally, preliminary data from patients with inflammatory disorders, as well as medically healthy depressed patients, suggest that inhibiting proinflammatory cytokines or their signaling pathways may improve depressed mood and increase treatment response to conventional antidepressant medication. Translational implications of these findings include the unique opportunity to identify relevant patient populations, apply immune-targeted therapies, and monitor therapeutic efficacy at the level of the immune system in addition to behavior.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19150053      PMCID: PMC2680424          DOI: 10.1016/j.biopsych.2008.11.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  117 in total

1.  Brain-immune communication pathways.

Authors:  Ning Quan; William A Banks
Journal:  Brain Behav Immun       Date:  2007-06-28       Impact factor: 7.217

Review 2.  Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression.

Authors:  Rainald Mössner; Olya Mikova; Eleni Koutsilieri; Mohamed Saoud; Ann-Christince Ehlis; Norbert Müller; Andreas J Fallgatter; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2007       Impact factor: 4.132

Review 3.  Neuroinflammation and regulation of glial glutamate uptake in neurological disorders.

Authors:  Sébastien Tilleux; Emmanuel Hermans
Journal:  J Neurosci Res       Date:  2007-08-01       Impact factor: 4.164

Review 4.  Autonomic innervation and regulation of the immune system (1987-2007).

Authors:  Dwight M Nance; Virginia M Sanders
Journal:  Brain Behav Immun       Date:  2007-04-27       Impact factor: 7.217

5.  Anterior cingulate cortex, error detection, and the online monitoring of performance.

Authors:  C S Carter; T S Braver; D M Barch; M M Botvinick; D Noll; J D Cohen
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

6.  Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways.

Authors:  G E Hardingham; Y Fukunaga; H Bading
Journal:  Nat Neurosci       Date:  2002-05       Impact factor: 24.884

7.  Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.

Authors:  Tyvin Rich; Pasquale F Innominato; Julie Boerner; M Christine Mormont; Stefano Iacobelli; Benoit Baron; Claude Jasmin; Francis Lévi
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

Review 8.  Why rejection hurts: a common neural alarm system for physical and social pain.

Authors:  Naomi I Eisenberger; Matthew D Lieberman
Journal:  Trends Cogn Sci       Date:  2004-07       Impact factor: 20.229

9.  Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.

Authors:  U S Kammula; D E White; S A Rosenberg
Journal:  Cancer       Date:  1998-08-15       Impact factor: 6.860

10.  Glial reduction in the subgenual prefrontal cortex in mood disorders.

Authors:  D Ongür; W C Drevets; J L Price
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more
  1142 in total

1.  Role of Macrophage Dopamine Receptors in Mediating Cytokine Production: Implications for Neuroinflammation in the Context of HIV-Associated Neurocognitive Disorders.

Authors:  R A Nolan; R Muir; K Runner; E K Haddad; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2018-12-05       Impact factor: 4.147

Review 2.  The heritability of postpartum depression.

Authors:  Elizabeth J Corwin; Ruth Kohen; Monica Jarrett; Brian Stafford
Journal:  Biol Res Nurs       Date:  2010-05-07       Impact factor: 2.522

3.  Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine.

Authors:  Peggy Jungke; Gigi Ostrow; Jian-Liang Li; Sharon Norton; Karen Nieber; Olaf Kelber; Veronika Butterweck
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

Review 4.  Advances in understanding mechanisms and therapeutic targets to treat comorbid depression and cardiovascular disease.

Authors:  Brittany S Pope; Susan K Wood
Journal:  Neurosci Biobehav Rev       Date:  2020-06-26       Impact factor: 8.989

5.  Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol.

Authors:  Charles L Raison; David B Rye; Bobbi J Woolwine; Gerald J Vogt; Breanne M Bautista; James R Spivey; Andrew H Miller
Journal:  Biol Psychiatry       Date:  2010-05-26       Impact factor: 13.382

Review 6.  BDNF function as a potential mediator of bipolar disorder and post-traumatic stress disorder comorbidity.

Authors:  J J Rakofsky; K J Ressler; B W Dunlop
Journal:  Mol Psychiatry       Date:  2011-09-20       Impact factor: 15.992

7.  Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.

Authors:  Patricia A Zunszain; Christoph Anacker; Annamaria Cattaneo; Shanas Choudhury; Ksenia Musaelyan; Aye Mu Myint; Sandrine Thuret; Jack Price; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

8.  Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.

Authors:  Jennifer L Warner-Schmidt; Kimberly E Vanover; Emily Y Chen; John J Marshall; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

9.  Transcriptomic predictors of inflammation-induced depressed mood.

Authors:  Joshua Hyong-Jin Cho; Michael R Irwin; Naomi I Eisenberger; Donald M Lamkin; Steve W Cole
Journal:  Neuropsychopharmacology       Date:  2019-01-14       Impact factor: 7.853

Review 10.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.